Angion Biomedica Corp.

NasdaqGS:ANGN 株式レポート

時価総額：US$30.1m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Angion Biomedica マネジメント

マネジメント 基準チェック /34

Angion Biomedicaの CEO はJay Venkatesanで、 May2018年に任命され、 の在任期間は 5.08年です。 の年間総報酬は$ 1.52Mで、 40%給与と60%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の3.98%を直接所有しており、その価値は$ 1.20M 。経営陣と取締役会の平均在任期間はそれぞれ3.5年と4.3年です。

主要情報

Jay Venkatesan

最高経営責任者

US$1.5m

報酬総額

CEO給与比率40.0%
CEO在任期間5.1yrs
CEOの所有権4.0%
経営陣の平均在職期間3.5yrs
取締役会の平均在任期間4.3yrs

経営陣の近況

Recent updates

Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Apr 27
Companies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite Risky

Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

Jan 05
Angion Biomedica (NASDAQ:ANGN) Will Have To Spend Its Cash Wisely

We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Sep 11
We Think Angion Biomedica (NASDAQ:ANGN) Needs To Drive Business Growth Carefully

Angion Biomedica GAAP EPS of -$0.30, revenue of $0.7M misses by $0.08M

Aug 15

Angion to discontinue phase 2 trial of ANG-3070 in patients with kidney disease

Jun 29

We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Mar 19
We Think Angion Biomedica (NASDAQ:ANGN) Can Afford To Drive Business Growth

Angion Biomedica: Selling At Cash Value

Feb 07

Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

Oct 05
Angion Biomedica Corp.'s (NASDAQ:ANGN) Intrinsic Value Is Potentially 49% Above Its Share Price

We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

Aug 18
We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely

CEO報酬分析

Angion Biomedica の収益と比較して、Jay Venkatesan の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$2mUS$608k

-US$39m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$32m

Dec 31 2021US$3mUS$587k

-US$55m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$100m

Mar 31 2021n/an/a

-US$104m

Dec 31 2020US$1mUS$570k

-US$80m

Sep 30 2020n/an/a

-US$67m

Dec 31 2019US$2mUS$473k

-US$41m

報酬と市場: Jayの 総報酬 ($USD 1.52M ) は、 US市場 ($USD 647.72K ) の同規模の企業の平均を上回っています。

報酬と収益: Jayの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jay Venkatesan (51 yo)

5.1yrs

在職期間

US$1,518,849

報酬

Dr. Jay R. Venkatesan, Ph D., M.D. MBA., serves as Chairman of Angion Biomedica Corp. since January 2022 and also serves as its President since January 2019 and has been its Chief Executive Officer & Direc...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jay Venkatesan
President5.1yrsUS$1.52m3.98%
$ 1.2m
Jennifer Rhodes
Executive VP3.4yrsUS$773.65k0.048%
$ 14.6k
Gregory Curhan
Chief Financial Officer3yrsUS$1.38m0.013%
$ 4.0k
Daniel Iazzetti
Vice President of Human Resources3.7yrsデータなしデータなし

3.5yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: ANGNの経営陣は 経験豊富 であると考えられます ( 3.5年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Jay Venkatesan
President5.1yrsUS$1.52m3.98%
$ 1.2m
Victor Ganzi
Lead Independent Non-Employee Director5.2yrsUS$93.78k3.25%
$ 978.7k
Gilbert Omenn
Independent Non-Employee Director3.4yrsUS$76.78k0.27%
$ 80.3k
Karen Wilson
Independent Non-Employee Director3.2yrsUS$81.28k0.062%
$ 18.7k
Joseph Bonventre
Chairperson of Scientific Advisory Boardno dataデータなしデータなし
Allen Nissenson
Independent Non-Employee Director3.4yrsUS$78.78k0.031%
$ 9.4k
Anupam Agarwal
Member of Scientific Advisory Boardno dataデータなしデータなし
Itzhak Goldberg
Chairman Emeritus25.2yrsUS$854.33k5.61%
$ 1.7m
Matthew Cooper
Member of Scientific Advisory Boardno dataデータなしデータなし
Matthew Weir
Member of Scientific Advisory Boardno dataデータなしデータなし
Michael Koren
Member of Scientific Advisory Boardno dataデータなしデータなし
Sumit Mohan
Member of Scientific Advisory Boardno dataデータなしデータなし

4.3yrs

平均在職期間

74yo

平均年齢

経験豊富なボード: ANGNの 取締役会 は 経験豊富 であると考えられます ( 4.3年の平均在任期間)。